BALDUZZI, ADRIANA CRISTINA
 Distribuzione geografica
Continente #
NA - Nord America 13.101
AS - Asia 8.958
EU - Europa 6.191
SA - Sud America 1.519
AF - Africa 154
OC - Oceania 40
Continente sconosciuto - Info sul continente non disponibili 5
Totale 29.968
Nazione #
US - Stati Uniti d'America 12.771
SG - Singapore 3.078
VN - Vietnam 1.805
CN - Cina 1.735
HK - Hong Kong 1.324
IT - Italia 1.320
BR - Brasile 1.203
RU - Federazione Russa 1.101
DE - Germania 790
IE - Irlanda 744
SE - Svezia 744
GB - Regno Unito 317
UA - Ucraina 295
CA - Canada 194
IN - India 185
ID - Indonesia 165
FR - Francia 161
FI - Finlandia 152
KR - Corea 141
AR - Argentina 112
MX - Messico 96
JP - Giappone 95
ES - Italia 94
BD - Bangladesh 89
TR - Turchia 89
AT - Austria 83
PL - Polonia 80
NL - Olanda 79
ZA - Sudafrica 64
EC - Ecuador 60
BE - Belgio 47
IQ - Iraq 39
IR - Iran 35
LT - Lituania 34
CO - Colombia 32
AU - Australia 31
CL - Cile 31
DK - Danimarca 28
EG - Egitto 23
PY - Paraguay 23
PK - Pakistan 21
AE - Emirati Arabi Uniti 19
CZ - Repubblica Ceca 19
VE - Venezuela 18
IL - Israele 17
PE - Perù 16
TW - Taiwan 16
UY - Uruguay 16
MA - Marocco 15
GR - Grecia 13
JO - Giordania 13
PT - Portogallo 13
UZ - Uzbekistan 13
CH - Svizzera 12
KE - Kenya 12
KZ - Kazakistan 11
PH - Filippine 11
TN - Tunisia 11
BG - Bulgaria 9
NZ - Nuova Zelanda 9
RS - Serbia 8
SA - Arabia Saudita 8
BO - Bolivia 7
MY - Malesia 7
PA - Panama 7
RO - Romania 7
SK - Slovacchia (Repubblica Slovacca) 7
DZ - Algeria 6
HN - Honduras 6
LA - Repubblica Popolare Democratica del Laos 6
NO - Norvegia 6
AL - Albania 5
DO - Repubblica Dominicana 5
JM - Giamaica 5
LV - Lettonia 5
NG - Nigeria 5
NP - Nepal 5
TT - Trinidad e Tobago 5
EU - Europa 4
NI - Nicaragua 4
OM - Oman 4
TH - Thailandia 4
AZ - Azerbaigian 3
BA - Bosnia-Erzegovina 3
CI - Costa d'Avorio 3
CR - Costa Rica 3
ET - Etiopia 3
HU - Ungheria 3
QA - Qatar 3
SN - Senegal 3
SY - Repubblica araba siriana 3
AM - Armenia 2
BH - Bahrain 2
BY - Bielorussia 2
EE - Estonia 2
GT - Guatemala 2
HR - Croazia 2
IS - Islanda 2
KG - Kirghizistan 2
KW - Kuwait 2
Totale 29.944
Città #
Ann Arbor 2.176
Singapore 1.656
Hong Kong 1.317
Ashburn 1.162
Fairfield 1.012
Woodbridge 810
Dublin 723
Wilmington 595
Ho Chi Minh City 567
Chandler 524
Houston 488
Hanoi 459
Seattle 449
Frankfurt am Main 434
Dallas 377
Milan 364
New York 363
Santa Clara 348
Hefei 324
Cambridge 287
Dearborn 286
Jacksonville 260
Beijing 250
Los Angeles 246
Princeton 232
Moscow 163
Seoul 135
Jakarta 129
Chicago 128
São Paulo 126
Lawrence 113
Shanghai 104
Buffalo 96
Nanjing 96
Altamura 92
The Dalles 88
Munich 81
San Diego 74
Rome 73
Nuremberg 58
Rio de Janeiro 56
London 55
Denver 53
Tokyo 53
Da Nang 52
Warsaw 52
Montreal 48
Andover 47
Haiphong 47
Ha Long 45
Toronto 42
Guangzhou 41
Biên Hòa 39
Helsinki 39
Orem 39
Turku 39
Chennai 38
Salt Lake City 38
Dong Ket 37
Quận Bình Thạnh 37
Lachine 36
Lappeenranta 36
Fremont 35
Poplar 34
Vienna 34
Council Bluffs 33
Johannesburg 33
Kent 33
Brussels 32
Mexico City 32
Nanchang 32
Boardman 31
Brooklyn 31
Changsha 30
Lissone 30
Stockholm 30
Tianjin 30
Hải Dương 29
Atlanta 27
Phoenix 27
Hangzhou 26
Thái Nguyên 26
Hebei 25
Dhaka 24
Quận Một 24
Ankara 23
Boston 23
Elk Grove Village 23
Paris 23
Buenos Aires 22
Naples 22
San Jose 22
Shenyang 22
Turin 22
Can Tho 21
Quận Phú Nhuận 21
Belo Horizonte 20
Brasília 20
Jinan 20
Kocaeli 20
Totale 19.246
Nome #
ABO incompatibile graft management in pediatric transplantation 589
Hormonal replacement therapy in adolescents and young women with chemo- or radio-induced premature ovarian insufficiency: Practical recommendations 460
Busulfan–fludarabine- or treosulfan–fludarabine-based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties 446
Long-term complications after allogeneic hematopoietic stem cell transplantation for pediatric patients with acute leukemia or myelodysplastic syndrome given either a Treosulfan- or a Busulfan-based conditioning regimen: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospective study 437
Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients 423
Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation 391
Cardiofaciocutaneous syndrome and immunodeficiency: data from an international multicenter cohort 390
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities 374
Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation 358
Avascular necrosis of the talus in pediatric acute lymphoblastic leukemia: Current concepts 353
Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring 343
Combined CAR-T/HSCT approach in a patient with refractory acute lymphoblastic leukemia and cystic fibrosis 342
Fertility preservation issues in pediatric hematopoietic stem cell transplantation: Practical approaches from the consensus of the Pediatric Diseases Working Party of the EBMT and the International BFM Study Group 323
Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Human Mesenchymal Stromal Cells: A Phase 1 Study On 47 Adult and Pediatric Patients 314
Interleukin-17-producing t-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation 313
T cells stimulated by CD40L positive leukemic blasts-pulsed dendritic cells meet optimal functional requirements for adoptive T-cell therapy 307
Children with cancer in the time of COVID-19: An 8-week report from the six pediatric onco-hematology centers in Lombardia, Italy 298
Regulatory T cells and extracorporeal photochemotherapy: correlation with clinical response and decreased frequency of proinflammatory T cells. 296
Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations 288
Mesenchymal stromal cells do not increase the risk of viral reactivation nor the severity of viral events in recipients of allogeneic stem cell transplantation 276
Hepatic focal nodular hyperplasia after pediatric hematopoietic stem cell transplantation: The impact of hormonal replacement therapy and iron overload 276
Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hemato-oncology center embedded within a COVID-19 dedicated hospital in Lombardia, Italy. Estote parati 276
Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population 273
State-of-the-art fertility preservation in children and adolescents undergoing haematopoietic stem cell transplantation: a report on the expert meeting of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT) in Baden, Austria, 29-30 September 2015 267
Autologous Purified Peripheral Blood Stem Cell Transplantation Compare to Chemotherapy in Childhood Acute Lymphoblastic Leukemia after Low-Risk Relapse 266
CD34(+) stem cell recovery after positive selection of "overloaded" immunomagnetic columns 259
High EVI1 Expression due to NRIP1/EVI1 Fusion in Therapy-related Acute Myeloid Leukemia: Description of the First Pediatric Case 250
Thyroid disorders following hematopoietic stem cell transplantation in childhood: the impact of the conditioning regimen on thyroid dysfunction, volume changes and occurrence of nodules 244
Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. 241
Bath PUVA therapy in pediatric patients with drug-resistant cutaneous graft-versus-host disease 239
A novel homozygous disruptive PRF1 variant (K285Sfs*4) causes very early-onset of familial hemophagocytic lymphohystiocytosis type 2 238
PENTRAXIN 3 PLASMA LEVELS AT GRAFT-VERSUS-HOST DISEASE ONSET PREDICT DISEASE SEVERITY AND RESPONSE TO THERAPY IN CHILDREN GIVEN HEMATOPOIETIC STEM CELL TRANSPLANTATION 236
Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient 233
TBI, etoposide and cyclophosphamide as a promising conditioning regimen for BMT in childhood ALL in second remission 227
Long-term effects of bone marrow transplantation on dental status in children with leukaemia 226
Pediatric immune myelofibrosis (PedIMF) as a novel and distinct clinical pathological entity 225
Iron Overload Following Hematopoietic Stem Cell Transplantation: Prevalence, Severity, and Management in Children and Adolescents with Malignant and Nonmalignant Diseases 224
Germ-Line TP53 Mutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition 224
Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? 223
Transplantation in Children and Adolescents with Acute Lymphoblastic Leukemia from a Matched Donor versus an HLA-Identical Sibling: Is the Outcome Comparable? Results from the International BFM ALL SCT 2007 Study 216
Precision-based exercise as a new therapeutic option for children and adolescents with haematological malignancies 212
Thyroid function disorders and secondary cancer following haematopoietic stem cell transplantation in pediatrics: State of the art and practical recommendations for a risk-based follow-up 211
When to suspect GATA2 deficiency in pediatric patients: from complete blood count to diagnosis 208
Pentraxin-3 Increases At The Onset Of Graft-Versus-Host Disease In Transplanted Patients 207
Febrile complications in the first 100 days after bone marrow transplantation in children: a single center's experience 206
Donor selection in Adults and Pediatrics 206
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation 204
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia 203
Impact of marrow unrelated donor search duration on outcome of children with acute lymphoblastic leukemia in second remission 201
Pubertal attainment and Leydig cell function following pediatric hematopoietic stem cell transplantation: a three-decade longitudinal assessment 199
Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience 198
Carcik-CD19 Cells Expand In Vivo Toward a CD8+ Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response 193
Response to rituximab-based therapy and risk factor analysis in epstein barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: A study from the infectious diseases working party of the european group for blood and marrow transplantation 191
Red blood cell support and alloimmunization rate against erythrocyte antigens in patients undergoing hematopoietic stem cell transplantation 188
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study 187
Extracorporeal photochemotherapy for the treatment of chronic graft-versus-host disease: trend for a possible cell dose-related effect? 185
Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment 185
Prospective study on allogeneic bone marrow transplantation (allo BMT) versus chemotherapy (chemo) for very high-risk (vhr) childhood acute lymphoblastic leukaemia in first complete remission 183
The impact of MRD in HCT for childhood ALL 183
Transplant-related toxicity and mortality: An AIEOP prospective study in 636 pediatric patients transplanted for acute leukemia 182
Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome 179
The role of haematopoietic stem cell transplantation for sickle cell disease in the era of targeted disease-modifying therapies and gene editing 179
Transplantation in childhood very high risk acute lymphoblastic leukemia in first complete remission: where are we now? 178
Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: The impact of the waiting time 176
Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation 174
Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: Comparison by genetic randomisation in an international prospective study 173
Reconstitution of lymphocyte subpopulations in children with inherited metabolic storage diseases after haematopoietic cell transplantation 173
Allogeneic bone marrow transplantation versus chemotherapy in high-risk childhood acute lymphoblastic leukaemia in first remission 172
Mechanical and infective central venous catheter-related complications: a prospective non-randomized study using Hickman and Groshong catheters in children with hematological malignancies 172
The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG 171
Endocrine, auxological and metabolic profile in children and adolescents with Down syndrome: from infancy to the first steps into adult life 169
Childhood cancer in Italy: background, goals, and achievements of the Italian Paediatric Hematology Oncology Association (AIEOP) 169
Pelvic ultrasound and pubertal attainment in girls with sexual precocity: the pivotal role of uterine volume in predicting the timing of menarche 168
A persistent severe autoimmune hemolytic anemia despite apparent direct antiglobulin test negativization 168
Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: Results from a phase III trial 167
Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 children 163
Autologous purified peripheral blood SCT in childhood low-risk relapsed ALL 163
Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution in a single-centre cohort 163
Case Report: Successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy 162
Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: A new classification from the European society for blood and marrow transplantation 162
Purified autologous grafting in childhood acute lymphoblastic leukemia in second remission: evidence for long-term clinical and molecular remissions 161
Tetralogy of Fallot with absent pulmonary valve: definitive diagnosis by two-dimensional echocardiography 158
Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT) 158
COVID-19 in Immunosuppressed Children 158
Successful sequential liver and hematopoietic stem cell transplantation in a patient with Fanconi anemia 157
Serum anti-Müllerian hormone as a marker of ovarian reserve after cancer treatment and/or hematopoietic stem cell transplantation in childhood: proposal for a systematic approach to gonadal assessment 157
First-Line Postremission Blinatumomab as Successful Toxicity-Sparing Strategy in a Boy with Cystic Fibrosis and Acute Lymphoblastic Leukemia 154
Isolated leukopenia in children and adolescents referred to a Pediatric Hematology Clinic 153
Effectiveness of extracorporeal photochemotherapy in treating long-term refractory chronic graft-versus-host disease 153
Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes 153
A novel flow-cytometric based method to assess post-HSCT donor chimerism exploiting RNA hybridization 152
Questions on chimerism analysis after stem cell transplantation 148
aGvHDtrackR and cGvHDtrackR: shiny applications for graft versus host disease management and clinical data collection 147
Two pregnancies shortly after transplantation with reduced intensity conditioning in chronic myeloid leukemia 146
Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study 146
Sport therapy: Allenamento di precisione dalla diagnosi al termine del trattamento oncologico in bambini e adolescenti con emopatia maligna [Sport therapy: Precision exercise training from diagnosis to the end of treatment in children/adolescents with malignant hemopathies] 145
The Impact of a Precision-Based Exercise Intervention in Childhood Hematological Malignancies Evaluated by an Adapted Yo-Yo Intermittent Recovery Test 145
More precisely defining risk peri-HCT in pediatric ALL: Pre- vs post-MRD measures, serial positivity, and risk modeling 141
Long-Term Host Immune Modulation Following Tisagenlecleucel Administration in Patients with Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic Leukemia 141
Moebius syndrome and hypopituitarism: a case of multiple pituitary hormone deficiency and revision of the literature 140
Totale 22.530
Categoria #
all - tutte 103.773
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 103.773


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.691 0 0 0 0 0 276 278 222 190 270 190 265
2021/20221.750 158 231 229 159 78 113 74 86 129 122 130 241
2022/20232.682 318 716 163 186 225 418 53 195 217 25 92 74
2023/20242.385 77 69 133 123 300 544 458 88 238 54 77 224
2024/20256.752 345 882 361 307 455 259 311 244 674 862 752 1.300
2025/20269.505 2.332 1.384 1.289 2.015 1.790 695 0 0 0 0 0 0
Totale 30.867